Rivercell Raises $25M Seed to Build an AI World Model of the Cell
The startup will use the funds to expand its wet lab and build data infrastructure for an AI model that predicts cell responses.
8 Articles
8 Articles
Rivercell raises $25M seed to build an AI world model of the cell
Paris start-up Rivercell has raised a $25M seed round to build an AI model that predicts how human cells respond to drugs and genetic changes. HV led the round, with HCVC, Alven and Bpifrance Digital Venture taking part, the company said on Wednesday. The money will pay for Rivercell’s data platform, a bigger wet lab […] This story continues at The Next Web
Financial Post
01netRivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment
Founded by serial entrepreneur and CEO, Yann Fleureau, and former AI research leader at Novartis and Owkin Eric Durand, Rivercell aims to generate high-resolution data on how human cells respond to treatments at scale and train AI models to predict their effects, ultimately accelerating the discovery and development of cures. Seed round led by HV, […]
Rivercell, founded by serial entrepreneur and CEO Yann Fleureau and Eric Durand, former head of AI research at Novartis and Owkin, aims to generate high-resolution data on a large scale regarding how human cells respond to treatments. Additionally, the company trains AI models to predict the effects thereof, with the ultimate goal of accelerating […]
PARIS--(BUSINESS WIRE)--A Rivercell, a biotechnology and AI company based in Paris, which has been building its own data infrastructure on how human cells respond to any treatment and training a global model of the cell capable of predicting these responses, today announced an initial investment round of $25 million led by HV. HCVC, Alven and Bpifrance Digital Venture also participated in the round, which will finance the expansion of the propri…
The Parisian startup Rivercell got $25 million to develop an AI that seeks to anticipate how human cells change to drugs and genetic modifications. Your bet depends on producing your own data through living cell experiments, a strategy that will also fund a larger laboratory in Paris.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
